Drug-Induced Gambling Disorder: Epidemiology, Neurobiology, and Management.
Level 5 - mechanism / opinion, no new human data
Narrative review of epidemiological, clinical, and neurobiological literature with no systematic review methodology described.
PubMed 36611111 · doi:10.1007/s40290-022-00453-9
What was done
This paper reviewed epidemiological, clinical, and neurobiological literature on the association between dopaminergic medications (specifically dopamine agonists like pramipexole and ropinirole, and the antipsychotic aripiprazole) and gambling disorder (GD). It evaluated vulnerable populations (such as patients with Parkinson's disease, restless legs syndrome, and psychotic disorders), neurobiological reward mechanisms, and existing treatment approaches.
What was found
The abstract reports no quantitative figures or statistical values. It notes that dopaminergic agents alter reward-related learning and impulse control through mesocorticolimbic dopamine signaling and the nucleus accumbens, likely precipitated by reward uncertainty. A causal link between these medications and GD is supported, though precise molecular mechanisms, compound-specific risk profiles, and interventional clinical trial data regarding medication tapering or targeted therapies remain limited.
Why it matters
This review outlines the clinical connection between commonly prescribed dopaminergic agents and impulse control disorders, highlighting the need for clinician vigilance in vulnerable patient populations and identifying a critical lack of interventional management trials.
Limits
The abstract describes a non-systematic narrative review with no defined search protocol, study selection criteria, or quantitative synthesis. It notes that molecular mechanisms remain incompletely characterized, differentiation of risk between specific compounds is poorly defined, and very few interventional studies exist to guide clinical management or drug tapering.